R1295
Description
Type: small molecule
Groups: investigational
Indication: Investigated for use/treatment in rheumatoid arthritis.
Accession Number: DB05122 ( DB05122)
Description: R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|
Brand Name | Ingredients |
---|
Categories
- No Category
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: R1295 is an integrin antagonist. As leukocyte integrins are key molecules in immune-mediated and inflammatory processes, R1295 may treat human inflammatory diseases such as rheumatoid arthritis.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Not Available
Dosage forms
Form | Route | Strength |
---|
Form | Route | Strength |
---|
Prices
Unit description | Cost | Unit |
---|
Unit description | Cost | Unit |
---|
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|
Interactions
Drug | Interaction |
---|
Drug | Interaction |
---|
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
General Reference: Not Available
External Links:
Resource | Link |
---|
Resource | Link |
---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download